AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39752644 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media recruitment
Number of subjects: 1227
Study 39752644 — intervention group
Group type: EXPERIMENTAL
Intervention: Dating app recruitment
Number of subjects: 1227
Study 39752644 — intervention group
Group type: EXPERIMENTAL
Intervention: Other digital sources recruitment
Number of subjects: 1227
Study 39752660 — intervention group
Group type: EXPERIMENTAL
Intervention: CSD surgery
Number of subjects: 88
Study 39753033 — intervention group
Group type: EXPERIMENTAL
Intervention: ConM SOSIP and ConS UFO immunogens (unmodified or stabilised by chemical cross-linking) followed by Mos3.1 and Mos3.2
Number of subjects: 51
Study 39753033 — intervention group
Group type: EXPERIMENTAL
Intervention: Mos3.1 and Mos3.2 immunogens
Number of subjects: 51
Study 39753033 — intervention group
Group type: EXPERIMENTAL
Intervention: ConM and ConS immunogens
Number of subjects: 51
Study 39753245 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU follow-up care bundle including diaries, information packages, and specialised follow-up care at 1 and 3 months post-discharge.
Number of subjects: 20
Study 39753245 — intervention group
Group type: COMPARATOR
Intervention: Standard of care in the ICU and follow-up with their primary care physician (PCP).
Number of subjects: 20
Study 39753246 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI (8 cycles)
Number of subjects: 60
Study 39753246 — intervention group
Group type: COMPARATOR
Intervention: XELOX (5 additional cycles)
Number of subjects: 60
Study 39753249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough Peak Flow (CPF-invol)
Number of subjects: 785
Study 39753249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough Peak Flow (CPF-vol)
Number of subjects: 785
Study 39753249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough Peak Flow (CPF-invol) for conscious patients
Number of subjects: 785
Study 39753249 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful extubation cases
Number of subjects: 785
Study 39753253 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically tailored groceries (MTGs)
Number of subjects: 60
Study 39753253 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically tailored groceries (MTGs) and food resource coaching
Number of subjects: 60
Study 39753253 — intervention group
Group type: COMPARATOR
Intervention: Usual pantry services (control)
Number of subjects: 60
Study 39753253 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (MTGs, MTGs and food resource coaching, and control)
Number of subjects: 60
Study 39753262 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised acute normovolaemic haemodilution (ANH) guided by the West China Liu's Score
Number of subjects: 0
Study 39753262 — intervention group
Group type: COMPARATOR
Intervention: Current clinical practice (Control group)
Number of subjects: 0
Study 39753264 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice-based technology (VB) for diabetes distress management
Number of subjects: 12
Study 39753264 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice-based technology (VB)
Number of subjects: 12
Study 39753269 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand acceleration time (HAT) measured at the radial, ulnar and four hand arteries before and after surgery
Number of subjects: 126
Study 39753269 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of HAIDI
Number of subjects: 126
Study 39753269 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular access patency
Number of subjects: 126
Study 39753269 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of complications
Number of subjects: 126
Study 39753296 — intervention group
Group type: EXPERIMENTAL
Intervention: jaktinib 100 mg two times per day
Number of subjects: 107
Study 39753296 — intervention group
Group type: EXPERIMENTAL
Intervention: jaktinib 75 mg two times per day
Number of subjects: 107
Study 39753296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 39753401 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous preoperative estimated glomerular filtration rate (eGFR)
Number of subjects: 44034
Study 39753402 — intervention group
Group type: EXPERIMENTAL
Intervention: Early noninvasive ventilation (NIV)
Number of subjects: 524
Study 39753402 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 524
Study 39753404 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine support
Number of subjects: 71927
Study 39753404 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71927
Study 39753485 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan-hziy (10 mg/kg weekly on days 1 and 8 of 21-day cycles)
Number of subjects: 9
Study 39753485 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan-hziy
Number of subjects: 9
Study 39753553 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib, lenalidomide, and dexamethasone
Number of subjects: 55
Study 39753962 — intervention group
Group type: EXPERIMENTAL
Intervention: Single immunization with 50 GA2-infected mosquitoes (GA2-MB)
Number of subjects: 15
Study 39753962 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mock-immunization)
Number of subjects: 15
Study 39753970 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT221, a personalized, neoantigen-specific autologous T cell product derived from peripheral blood, tested in a 3 + 3 dose-finding study with two dose levels (DLs).
Number of subjects: 9
Study 39753998 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate and vigorous physical activity intensity cut-points for hip-, wrist-, thigh-, and lower back worn accelerometer
Number of subjects: 0
Study 39754101 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic knowledge of AI principles
Number of subjects: 384
Study 39754101 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of AI usage in dentistry
Number of subjects: 384
Study 39754101 — intervention group
Group type: EXPERIMENTAL
Intervention: Source of information for AI applications
Number of subjects: 384
Study 39754101 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement on AI's role in advancing dentistry
Number of subjects: 384
Study 39754101 — intervention group
Group type: EXPERIMENTAL
Intervention: Disagreement on AI replacing dentists
Number of subjects: 384
Study 39754101 — intervention group
Group type: EXPERIMENTAL
Intervention: Approval of AI in undergraduate training
Number of subjects: 384
Study 39754101 — intervention group
Group type: EXPERIMENTAL
Intervention: Approval of AI in postgraduate training
Number of subjects: 384
Study 39754106 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic birth position
Number of subjects: 630
Study 39754106 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum support
Number of subjects: 630
Study 39754106 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal protection
Number of subjects: 630
Study 39754106 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-led Quality Improvement intervention
Number of subjects: 630
Study 39754114 — intervention group
Group type: EXPERIMENTAL
Intervention: hPH injection
Number of subjects: 50
Study 39754114 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) injection
Number of subjects: 50
Study 39754130 — intervention group
Group type: EXPERIMENTAL
Intervention: GenV longitudinal cohort study
Number of subjects: 150000
Study 39754130 — intervention group
Group type: EXPERIMENTAL
Intervention: GenV assessments
Number of subjects: 150000
Study 39754134 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensor Indicis Proprius to EPL tendon transfer
Number of subjects: 13
Study 39754157 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered dietary education for 12 weeks
Number of subjects: 129
Study 39754157 — intervention group
Group type: COMPARATOR
Intervention: Regular care only (control group)
Number of subjects: 129
Study 39754194 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind programme (ACT and compassion-based intervention)
Number of subjects: 0
Study 39754194 — intervention group
Group type: COMPARATOR
Intervention: Support group intervention (active control)
Number of subjects: 0
Study 39754194 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (inactive control)
Number of subjects: 0
Study 39754254 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic and Endoscopic Cooperative Surgery (LECS)
Number of subjects: 0
Study 39754470 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS guided group
Number of subjects: 180
Study 39754470 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 39754489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial alteplase (0.225 mg/kg; maximum dose, 22.5 mg)
Number of subjects: 376
Study 39754489 — intervention group
Group type: COMPARATOR
Intervention: Standard care following successful thrombectomy (eTICI 2b ≥50)
Number of subjects: 376
Study 39754489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial alteplase
Number of subjects: 376
Study 39754648 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM)
Number of subjects: 36
Study 39754932 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin 6
Number of subjects: 1117
Study 39754932 — intervention group
Group type: COMPARATOR
Intervention: Control group (females)
Number of subjects: 1117
Study 39754932 — intervention group
Group type: EXPERIMENTAL
Intervention: Other biomarkers
Number of subjects: 1117
Study 39754976 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin plus letrozole (L)
Number of subjects: 1065
Study 39754976 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin plus zoledronic acid + letrozole (ZL)
Number of subjects: 1065
Study 39754976 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (T)
Number of subjects: 1065
Study 39755168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) 10 mg/kg on days 1 and 8 of a 21-day cycle
Number of subjects: 43
Study 39755168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 43
Study 39755436 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott Freestyle Libre Pro
Number of subjects: 30
Study 39755436 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G4 Platinum
Number of subjects: 30
Study 39755564 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Change Techniques (BCTs)
Number of subjects: 820
Study 39755564 — intervention group
Group type: COMPARATOR
Intervention: No BCTs (no-BCT condition)
Number of subjects: 820
Study 39755564 — intervention group
Group type: EXPERIMENTAL
Intervention: All four BCTs
Number of subjects: 820
Study 39755564 — intervention group
Group type: EXPERIMENTAL
Intervention: Unique combinations of BCTs (14 conditions)
Number of subjects: 820
Study 39755573 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2 (fraction of inspired oxygen)
Number of subjects: 200
Study 39755573 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy (control group)
Number of subjects: 200
Study 39755576 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal multiple micronutrient supplements (MMS) at varying doses up to ~75% of the tolerable upper intake level (UL)
Number of subjects: 240
Study 39755576 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (control arm)
Number of subjects: 240
Study 39755582 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib plus sintilimab (F&S) in RT cohort
Number of subjects: 55
Study 39755582 — intervention group
Group type: COMPARATOR
Intervention: Fruquintinib plus sintilimab (F&S) in non-RT cohort
Number of subjects: 55
Study 39755598 — intervention group
Group type: EXPERIMENTAL
Intervention: TCD pulsatility index guided norepinephrine titration
Number of subjects: 112
Study 39755598 — intervention group
Group type: COMPARATOR
Intervention: SSC guidelines for MAP ≥ 65 mmHg
Number of subjects: 112
Study 39755611 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM milling of new maxillary dentures (Group A)
Number of subjects: 12
Study 39755611 — intervention group
Group type: COMPARATOR
Intervention: Conventional relining method (Group B)
Number of subjects: 12
Study 39755716 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer survivors (BCSs)
Number of subjects: 140
Study 39755716 — intervention group
Group type: COMPARATOR
Intervention: Non-cancer controls
Number of subjects: 140
Study 39755925 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorecivivint (LOR) 0.07 mg
Number of subjects: 495
Study 39755925 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 495
Study 39755971 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of hydrocodone with 300 mg of acetaminophen (opioid)
Number of subjects: 1815
Study 39755971 — intervention group
Group type: COMPARATOR
Intervention: 400 mg of ibuprofen and 500 mg of acetaminophen (nonopioid)
Number of subjects: 1815
Study 39756018 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention in the INKA trial
Number of subjects: 217
Study 39756018 — intervention group
Group type: COMPARATOR
Intervention: Non-participation in the INKA trial (nINKA group)
Number of subjects: 217
Study 39756018 — intervention group
Group type: COMPARATOR
Intervention: Comparison of OKS between INKA and nINKA groups
Number of subjects: 217
Study 39756018 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary patient-reported outcomes in the INKA trial
Number of subjects: 217
Study 39756156 — intervention group
Group type: EXPERIMENTAL
Intervention: TNG908
Number of subjects: 0
Study 39756156 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 39756174 — intervention group
Group type: EXPERIMENTAL
Intervention: Get FIT + (intervention): personalized text messages with healthy lifestyle counselling, mHealth app (MyFitnessPal), and activity tracker.
Number of subjects: 54
Study 39756174 — intervention group
Group type: COMPARATOR
Intervention: Get FIT (control): healthy lifestyle counselling from a licensed health coach, mHealth app (MyFitnessPal), and activity tracker without personalized text messages.
Number of subjects: 54
Study 39756216 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted influenza A(H7N9) inactivated vaccine (A(H7N9) IIV)
Number of subjects: 0
Study 39756216 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year delayed boost with a heterologous adjuvanted A(H7N9) IIV
Number of subjects: 0
Study 39756216 — intervention group
Group type: COMPARATOR
Intervention: Concomitant seasonal influenza vaccination
Number of subjects: 0
Study 39756216 — intervention group
Group type: COMPARATOR
Intervention: Heterologous A(H7N9) IIVs in the 2-dose priming series
Number of subjects: 0
Study 39756216 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HA stalk antibody responses
Number of subjects: 0
Study 39756424 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanzacaftor-tezacaftor-deutivacaftor
Number of subjects: 971
Study 39756424 — intervention group
Group type: COMPARATOR
Intervention: Elexacaftor-tezacaftor-ivacaftor
Number of subjects: 971
Study 39756425 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanzacaftor-tezacaftor-deutivacaftor
Number of subjects: 78
Study 39756444 — intervention group
Group type: EXPERIMENTAL
Intervention: Belzutifan 120 mg orally once daily and cabozantinib 60 mg orally once daily
Number of subjects: 50
Study 39756446 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain radiotherapy combined with camrelizumab (200 mg intravenously once every 3 weeks) and platinum-doublet chemotherapy (pemetrexed 500 mg/m2)
Number of subjects: 65
Study 39756446 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy
Number of subjects: 65
Study 39756588 — intervention group
Group type: EXPERIMENTAL
Intervention: VR session (VRD group, n=178)
Number of subjects: 342
Study 39756588 — intervention group
Group type: EXPERIMENTAL
Intervention: VR session with hypnosis (VRH group, n=164)
Number of subjects: 342
Study 39756673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 352
Study 39756673 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 352
Study 39756693 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2601 plus PCV20 (combination group)
Number of subjects: 256
Study 39756693 — intervention group
Group type: COMPARATOR
Intervention: NVX-CoV2601 plus placebo (NVX-only group)
Number of subjects: 256
Study 39756693 — intervention group
Group type: COMPARATOR
Intervention: PCV20 plus placebo (PCV20-only group)
Number of subjects: 256
Study 39756693 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus placebo (placebo group)
Number of subjects: 256
Study 39756819 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (n=288)
Number of subjects: 1177
Study 39756819 — intervention group
Group type: COMPARATOR
Intervention: Men (n=889)
Number of subjects: 1177
Study 39756819 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sexes
Number of subjects: 1177
Study 39756820 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to hypoxia (ascending from 760 m to 3100 m for a 2-day stay)
Number of subjects: 54
Study 39756833 — intervention group
Group type: EXPERIMENTAL
Intervention: VLP Peanut
Number of subjects: 12
Study 39756844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel)
Number of subjects: 419
Study 39756844 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 419
Study 39757160 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic bidet
Number of subjects: 75
Study 39757160 — intervention group
Group type: COMPARATOR
Intervention: Sitz bath
Number of subjects: 75
Study 39757186 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg/day) administered orally for 2 weeks followed by 1 week off in a 3-week cycle, in combination with continued use of EGFR-TKIs.
Number of subjects: 120
Study 39757192 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (UK) 1,000,000 U
Number of subjects: 999
Study 39757192 — intervention group
Group type: COMPARATOR
Intervention: Best medicine treatment (control)
Number of subjects: 999
Study 39757368 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological risk assessment using PBSI
Number of subjects: 0
Study 39757368 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist's risk assessment
Number of subjects: 0
Study 39757748 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide (1.6 mg on days 1-21), ixazomib (3 mg on days 1, 8, 15), dexamethasone (20 mg on days 1, 8, 15, 22 for cycles 1-2; 10 mg on days 1, 8, 15, 22 for cycles 3-6)
Number of subjects: 70
Study 39757748 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide, ixazomib and dexamethasone (I2D)
Number of subjects: 70
Study 39757775 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured resection method
Number of subjects: 49
Study 39757775 — intervention group
Group type: COMPARATOR
Intervention: Traditional 'two-finger' method
Number of subjects: 49
Study 39757773 — intervention group
Group type: EXPERIMENTAL
Intervention: HES-I (Idiopathic Hypereosinophilia)
Number of subjects: 779
Study 39757908 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interview-based breastfeeding education (4 sessions)
Number of subjects: 76
Study 39757908 — intervention group
Group type: COMPARATOR
Intervention: Control group (no motivational interview-based education)
Number of subjects: 76
Study 39758009 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital twin-predicted sites
Number of subjects: 18
Study 39758009 — intervention group
Group type: COMPARATOR
Intervention: Nonpredicted sites
Number of subjects: 18
Study 39758130 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model using baseline and 6-month FAF images
Number of subjects: 597
Study 39758130 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model using FAF images collected 6 months after baseline
Number of subjects: 597
Study 39758130 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model using FAF images collected at baseline and 6 months
Number of subjects: 597
Study 39758223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical supplement (Clear Skin Formula; VitaMedica®) taken daily for 84 days
Number of subjects: 40
Study 39758223 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules taken daily for 84 days
Number of subjects: 40
Study 39758508 — intervention group
Group type: COMPARATOR
Intervention: BP-lowering treatment
Number of subjects: 11140
Study 39758508 — intervention group
Group type: COMPARATOR
Intervention: Intensive glucose-lowering treatment
Number of subjects: 11140
Study 39758592 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplement (SQ-LNS) provided to mothers during pregnancy and 6 months postpartum and to their children from 6 to 18 months.
Number of subjects: 966
Study 39758592 — intervention group
Group type: COMPARATOR
Intervention: Non-LNS group (control) receiving iron and folic acid or multiple micronutrients during pregnancy and postpartum.
Number of subjects: 966
Study 39758693 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam roller warm-up for three months plus one month follow-up without foam rolling
Number of subjects: 22
Study 39758693 — intervention group
Group type: COMPARATOR
Intervention: Control group with general warm-up for four months
Number of subjects: 22
Study 39758967 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated faecal microbiota transplantation (FMT)
Number of subjects: 40
Study 39758967 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 40
Study 39759424 — intervention group
Group type: EXPERIMENTAL
Intervention: Iclepertin 10 mg + CCT
Number of subjects: 200
Study 39759424 — intervention group
Group type: COMPARATOR
Intervention: Placebo + CCT
Number of subjects: 200
Study 39759832 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 47
Study 39760061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 0
Study 39760061 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39760219 — intervention group
Group type: EXPERIMENTAL
Intervention: IBBIS II (integrated mental health care and vocational rehabilitation)
Number of subjects: 900
Study 39760219 — intervention group
Group type: COMPARATOR
Intervention: Service as usual (SAU)
Number of subjects: 900